(figures in parentheses refer to the corresponding period in the previous year)
Net sales amounted to 0 (0).
Other operating income amounted to 577 (3,730) TSEK.
Operating profit (EBIT) amounted to -13,908 (-8,731) TSEK.
Profit after tax amounted to -13,909 (-8,795) TSEK.
Earnings per share before and after dilution: -0.01 (-0.01) SEK.
Cash flow from operating activities was -12,558 (-12,611) TSEK.
Period, January 1 – September 30, 2025
Net sales amounted to 0 (0).
Other operating income amounted to 3,185 (3,816) TSEK.
Operating profit (EBIT) amounted to -37,262 (-28,760) TSEK.
Profit after tax amounted to -37,585 (-28,948) TSEK.
Earnings per share before and after dilution: -0.03 (-0.03) SEK.
Cash flow from operating activities was -26,342 (-21,499) TSEK.
Significant events during the quarter
Fully Subscribed Rights Issue Prolight’s rights issue of SEK 100.3 million was fully subscribed. Approximately 70.2 percent was subscribed for with subscription rights and around 29.8 percent without subscription rights. The new shares have been registered with the Swedish Companies Registration Office (Bolagsverket) and delivered to the respective investors.
Patent Granted in Japan for Psyros Technology The Japan Patent Office (JPO) has granted Prolight a patent covering the Psyros single-molecule counting technology. The patent is valid until 2040.
Psyros Showcased at ADLM 2025 in Chicago Prolight showcased a fully functional commercial prototype of the Psyros system for the first time at the Association for Diagnostics & Laboratory Medicine (ADLM) international congress held in Chicago on 27–29 July 2025.
Positive European Patent Decision for Third Psyros Patent The European Patent Office (EPO) has issued a Notice of Intention to Grant for Prolight’s third patent application related to the Psyros technology.
Significant events after the end of the period
Preparations for Clinical Performance Study In the October and November investor letters, the company reported ongoing design and manufacturing improvements alongside preparations for pilot production and validation of manufacturing processes. Qualification activities for study sites in Europe have also commenced in preparation for the upcoming clinical performance study.
Extraordinary General Meeting 19 November 2025 The general meeting resolved, in accordance with the board’s proposal, to carry out a reverse share split (consolidation of shares) and to implement an incentive program for the employees of the UK subsidiary.
